choriogonadotropin alfa 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5149 177073-44-8

Description:

MoleculeDescription

Synonyms:

  • choriogonadotropin alfa
  • ovidrel
  • ovitrelle
Choriogonadotropin alfa, is an analogue of Luteinizing Hormone (LH) and binds to the LH/hCG receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge. In pregnancy, hCG, secreted by the placenta, maintains the viability of the corpus luteum to provide the continued secretion of estrogen and progesterone necessary to support the first trimester of pregnancy.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
0.25 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 20, 2000 FDA EMD SERONO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ovarian hyperstimulation syndrome 4262.25 48.42 605 2730 2639 50599150
Ascites 736.70 48.42 209 3126 35652 50566137
Ovarian haemorrhage 188.72 48.42 30 3305 282 50601507
Maternal exposure before pregnancy 181.53 48.42 47 3288 5550 50596239
Inappropriate schedule of product administration 157.50 48.42 82 3253 71749 50530040
Adnexal torsion 151.60 48.42 24 3311 219 50601570
Pelvic fluid collection 129.72 48.42 25 3310 758 50601031
Ovarian enlargement 123.90 48.42 22 3313 420 50601369
Haemoperitoneum 120.61 48.42 29 3306 2526 50599263
Pleural effusion 93.09 48.42 61 3274 81393 50520396
Abortion spontaneous 86.57 48.42 46 3289 41726 50560063
Multiple pregnancy 76.64 48.42 11 3324 47 50601742
Abdominal distension 72.24 48.42 50 3285 72853 50528936
Effusion 69.52 48.42 17 3318 1586 50600203
Intra-abdominal haemorrhage 68.82 48.42 18 3317 2202 50599587
Ectopic pregnancy 67.98 48.42 18 3317 2309 50599480
Abdominal pain lower 65.85 48.42 31 3304 21725 50580064
Ovarian cyst ruptured 55.37 48.42 13 3322 1020 50600769
Poor response to ovulation induction 51.77 48.42 6 3329 0 50601789
Infrequent bowel movements 49.00 48.42 12 3323 1126 50600663

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product packaging quantity issue 189.27 85.61 28 448 737 29573314
No adverse event 145.27 85.61 37 439 17441 29556610
Product dose omission issue 124.19 85.61 49 427 96334 29477717

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ovarian hyperstimulation syndrome 3753.34 50.25 510 2457 2335 64493430
Ascites 655.30 50.25 199 2768 61802 64433963
Ovarian haemorrhage 186.04 50.25 28 2939 265 64495500
Adnexal torsion 157.63 50.25 23 2944 172 64495593
Pelvic fluid collection 143.43 50.25 25 2942 623 64495142
Ovarian enlargement 138.70 50.25 22 2945 301 64495464
Maternal exposure before pregnancy 111.71 50.25 27 2940 3456 64492309
Haemoperitoneum 98.61 50.25 25 2942 3890 64491875
Pleural effusion 83.94 50.25 59 2908 126500 64369265
Multiple pregnancy 75.30 50.25 10 2957 33 64495732
Effusion 72.14 50.25 17 2950 1951 64493814
Ovarian cyst ruptured 62.39 50.25 13 2954 848 64494917
Abdominal distension 55.01 50.25 41 2926 95953 64399812
Abdominal pain lower 54.91 50.25 26 2941 26443 64469322
Intra-abdominal haemorrhage 51.12 50.25 15 2952 4016 64491749

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G03GA08 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
GONADOTROPINS AND OTHER OVULATION STIMULANTS
Gonadotropins
FDA CS M0009540 Gonadotropins
FDA EPC N0000175838 Gonadotropin

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Lutropin-choriogonadotropic hormone receptor GPCR AGONIST CHEMBL CHEMBL

External reference:

IDSource
6413W06WR3 UNII
4021245 VANDF
C0937609 UMLSCUI
CHEMBL1201464 ChEMBL_ID
D03478 KEGG_DRUG
DB00097 DRUGBANK_ID
7473 INN_ID
C412828 MESH_SUPPLEMENTAL_RECORD_UI
283550 RXNORM
15777 MMSL
38355 MMSL
129494006 SNOMEDCT_US
391878002 SNOMEDCT_US
009029 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ovidrel HUMAN PRESCRIPTION DRUG LABEL 1 44087-1150 INJECTION, SOLUTION 250 ug SUBCUTANEOUS BLA 23 sections